Published :
Tables : 57
Figures : 52
Category : Healthcare
No. of Pages : 244
Report Code : HC-U5432
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Overview: FutureWise Market Research has instantiated a report that provides an intricate analysis of Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market: • Pfizer, Inc. • Allergan Plc. • Johnsons & Johnson • Merck & Co., Inc. • Baxter Healthcare Corporation • Bausch Health Companies Inc. • Cumberland Pharmaceuticals Inc. • Mylan N.V. • Melinta Therapeutics, Inc. • Akron Pharma Inc. • Amneal Pharmaceuticals, Inc. • Herbal Intervention, LLC • Bio-Germ Protection LLC • Novartis AG • Debiopharm International SA • Fresenius Kabi LLC • Teva Pharmaceutical Industries Ltd. • Sun Pharmaceutical Industries Ltd. • Dr. Reddy’s Laboratories Ltd. • Mayne Pharma Group Limited. (Note: The list of the major players will be updated with the latest market scenario and trends) Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Segmentation: By Drug Type • Glycopeptides o Vancomycin • Lipopeptides o Daptomycin • Oxazolidinones o Linezolid • Glycylcycline o Tigecycline • Streptogramins o Quinupristin o Dalfopristin • Lincomycin o Clindamycin • Tetracycline o Doxycycline o Minocycline • Lipoglycopeptides o Dalbavancin o Telavancin o Oritavancin • Antiseptics o Chlorhexidine o Cetylpyridinium Chloride o Hydrogen Peroxide o Phenols • Naturals/Herbals • Others By Indication • Skin and Soft Tissue Infections (SSTIs) • Pneumonia • Bloodstream Infections • Surgical and Medical Infections • Others By Route of Administration • Intravenous • Oral • Topical • Nasal • Cutaneous • Intramuscular By Types of MRSA • Healthcare Acquired MRSA • Community Acquired MRSA • Hospital Acquired MRSA By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Drugstores • Online Pharmacies By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market By Drug Type, By Indication, By Route of Administration, Types of MRSA, By Distribution Channel and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has instantiated a report that provides an intricate analysis of Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market: • Pfizer, Inc. • Allergan Plc. • Johnsons & Johnson • Merck & Co., Inc. • Baxter Healthcare Corporation • Bausch Health Companies Inc. • Cumberland Pharmaceuticals Inc. • Mylan N.V. • Melinta Therapeutics, Inc. • Akron Pharma Inc. • Amneal Pharmaceuticals, Inc. • Herbal Intervention, LLC • Bio-Germ Protection LLC • Novartis AG • Debiopharm International SA • Fresenius Kabi LLC • Teva Pharmaceutical Industries Ltd. • Sun Pharmaceutical Industries Ltd. • Dr. Reddy’s Laboratories Ltd. • Mayne Pharma Group Limited. (Note: The list of the major players will be updated with the latest market scenario and trends)
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Segmentation: By Drug Type • Glycopeptides o Vancomycin • Lipopeptides o Daptomycin • Oxazolidinones o Linezolid • Glycylcycline o Tigecycline • Streptogramins o Quinupristin o Dalfopristin • Lincomycin o Clindamycin • Tetracycline o Doxycycline o Minocycline • Lipoglycopeptides o Dalbavancin o Telavancin o Oritavancin • Antiseptics o Chlorhexidine o Cetylpyridinium Chloride o Hydrogen Peroxide o Phenols • Naturals/Herbals • Others By Indication • Skin and Soft Tissue Infections (SSTIs) • Pneumonia • Bloodstream Infections • Surgical and Medical Infections • Others By Route of Administration • Intravenous • Oral • Topical • Nasal • Cutaneous • Intramuscular By Types of MRSA • Healthcare Acquired MRSA • Community Acquired MRSA • Hospital Acquired MRSA By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Drugstores • Online Pharmacies By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market By Drug Type, By Indication, By Route of Administration, Types of MRSA, By Distribution Channel and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market, By Drug Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Glycopeptides 7.1.1. Vancomycin 7.2. Lipopeptides 7.2.1. Daptomycin 7.3. Oxazolidinones 7.3.1. Linezolid 7.4. Glycylcycline 7.4.1. Tigecycline 7.5. Streptogramins 7.5.1. Quinupristin 7.5.2. Dalfopristin 7.6. Lincomycin 7.6.1 Clindamycin 7.7. Tetracycline 7.7.1. Doxycycline 7.7.2. Minocycline 7.8. Lipoglycopeptides 7.8.1. Dalbavancin 7.8.2. Telavancin 7.8.3. Oritavancin 7.9. Antiseptics 7.9.1. Chlorhexidine 7.9.2. Cetylpyridinium Chloride 7.9.3. Hydrogen Peroxide 7.9.4. Phenols 7.10. Naturals/Herbals 7.11. Others 8. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market, By Indication Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Skin and Soft Tissue Infections (SSTIs) 8.2. Pneumonia 8.3. Bloodstream Infections 8.4. Surgical and Medical Infections 8.5. Others 9. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market, By Route of Administration Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Intravenous 9.2. Oral 9.3. Topical 9.4. Nasal 9.5. Cutaneous 9.6. Intramuscular 10. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market, Types of MRSA Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Healthcare Acquired MRSA 10.2. Community Acquired MRSA 10.3. Hospital Acquired MRSA 11. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market, By Distribution Channel Historical Analysis and Forecast 2020-2027 (USD Million) 11.1. Hospital Pharmacies 11.2. Retail Pharmacies 11.3. Drugstores 11.4. Online Pharmacies 12. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2020-2027 13. Latin America Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2020-2027 14. Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2020-2027 15. Asia Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 16. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 16.2.1. Saudi Arabia 16.2.2. UAE 16.2.3. South Africa 16.2.4. Egypt 16.3. Market Size (USD Million) Forecast for MEA 2020-2027 17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix 18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Pfizer, Inc. 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Allergan Plc. 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. Johnsons & Johnson 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Merck & Co., Inc. 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5. Baxter Healthcare Corporation 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6. Bausch Health Companies Inc. 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Cumberland Pharmaceuticals Inc. 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. Mylan N.V. 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Melinta Therapeutics, Inc. 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10. Akron Pharma Inc. 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11. Amneal Pharmaceuticals, Inc. 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12. Herbal Intervention, LLC 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13. Bio-Germ Protection LLC 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14. Novartis AG 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15. Debiopharm International SA 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16. Fresenius Kabi LLC 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17. Teva Pharmaceutical Industries Ltd. 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18. Sun Pharmaceutical Industries Ltd. 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview 18.19. Dr. Reddy’s Laboratories Ltd. 18.19.1. Company Overview 18.19.2. Product Portfolio 18.19.3. SWOT Analysis 18.19.4. Financial Overview 18.19.5. Strategic Overview 18.20. Mayne Pharma Group Limited. 18.20.1. Company Overview 18.20.2. Product Portfolio 18.20.3. SWOT Analysis 18.20.4. Financial Overview 18.20.5. Strategic Overview 19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations 20. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics